AIM2 has been shown to impede the malignant behaviors of CRC cells, such as proliferation and migration, through modulation of the AKT/mTOR signaling pathway, NF-κB signaling pathway, Notch signaling pathway, mitochondrial dynamics, and cell cycle regulation, thereby exhibiting anti-tumor effects. The gene discussed is MTOR; the disease is colorectal carcinoma.